Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs T Rowe Price Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while T Rowe Price Group Inc trades at $113.73 (market cap $24.26B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TROW | |
|---|---|---|
Market Cap | $29.60B | $24.26B |
Sector | Health | Financials |
52-Week High | $491.22 | $121.68 |
52-Week Low | $205.48 | $86.19 |
Enterprise Value | $27.56B | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
T. Rowe Price (TROW) trades at $111.49, down 2.0% on the day, with a bearish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 11.42, net income margin of 29.26%, and consistent dividend payments of $1.30 per share. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51 estimated, driven by higher assets under management and advisory revenue.
The outlook is mixed: strong profitability and a consensus price target of $112.17 offer upside, but bearish technicals and expense pressures pose risks. Investor sentiment is cautious with 63% analyst hold ratings, reflecting concerns over net outflows and market volatility impacting asset management fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
